Announced Mon, 27 Apr · 08:59 IST
Chairman Vivek Sharma steps down, Umang Vohra named new Group CEO
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+36.1%1-day move
₹358.95
prior close
₹380.35
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+12.3+11.6+11.4+13.6+36.1+30.9+33.9+30.1+26.5+35.4+19.0+19.8+25.4+18.7
Up moveDown movePending
AI summary
Cohance Lifesciences announced major leadership changes. Executive Chairman Mr. Vivek Sharma will resign effective April 30, 2026, but will serve as Special Advisor for 9 months to aid transition. Mr. Umang Vohra has been appointed as Chairman (May 1) and Group CEO (May 20) for a 5-year term, subject to shareholder approval. Board also approved ESOP 2026 with 2.59 crore options (6.25% dilution), exercise price not less than Rs 325/share.
Likely market impact
Smooth leadership transition with 9-month advisor handover. New external CEO appointed. ESOP 2026 signals retention focus. Subject to shareholder approval.